Coherus Oncology has now signed at least three clinical collaboration and supply agreements to build out a combination data package for LOQTORZI, and the latest one reveals something strategically telling: the company is deliberately reaching into innate immunity to compensate for PD-1’s ceiling in solid tumors. The new Phase 1 trial with Zumutor Biologics pairs LOQTORZI with ZM008, an anti-LLT1 monoclonal antibody designed to release a brake on natural killer cells, enrolling up to 45 patients across colorectal, head and neck, non-small cell lung, clear cell renal cell, and urothelial cancers.
The business logic here is straightforward, even if the science is not. LOQTORZI earned its FDA approval in October 2023 for nasopharyngeal carcinoma, a relatively small commercial market in the United States. Expanding into NSCLC, head and neck squamous cell carcinoma, and other high-volume indications is the only way to justify the asset’s place in an oncology portfolio. Rather than fund independent investigator-initiated studies or carry full clinical costs alone, Coherus supplies the drug and Zumutor sponsors the trial. Each party retains commercial rights to its own compound. The arrangement generates US data cheaply, and any eventual signal lands on Coherus’s regulatory scorecard without a proportionate cash outlay.
The choice of LLT1 as the partner target is worth examining carefully. ZM008’s monotherapy data show clinical benefit in patients who previously progressed on immune checkpoint inhibitors, and the drug has produced no dose-limiting toxicities or anti-drug antibodies so far. LLT1 is an NK cell checkpoint that operates through the innate arm of the immune system, distinct from the adaptive T-cell pathways that PD-1 blockade addresses. The rationale is that “cold” tumors, those with minimal T-cell infiltration, might respond to a regimen that activates NK cells at the same time adaptive checkpoints are released. That hypothesis is clinically interesting but still early, and a 45-patient dose-escalation study is not powered to prove it.
Zumutor, which has raised roughly $33 million to date, gets something valuable beyond capital: a validated PD-1 partner with existing US clinical infrastructure and regulatory familiarity. For investors watching Coherus, the cleaner metric to track is whether LOQTORZI combination data in NSCLC or HNSCC reach a signal strong enough to support a registrational design, because that is the only path that meaningfully changes the drug’s addressable market.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
